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Objective. There is a strong need for biomarkers to identify patients at risk for future cardiovascular events related with progressive
atherosclerotic disease. Osteoprotegerin (OPG) protects the skeleton from excessive bone resorption by binding to receptor
activator of nuclear factor-κB ligand (RANKL) and preventing it from binding to its receptor, receptor activator of nuclear factor-
κB. However, conﬂicting results have been obtained about association of serum level of OPG or RANKL with coronary artery
disease (CAD). Based on their role in inﬂammation and matrix degradation and the fact that atherosclerotic plaque formation is
an inﬂammatory process, we hypothesized that RANKL:OPG ratio could be a better biomarker for CAD. Methods. In this cross-
sectional study, the correlation between RANKL:OPG ratio serum concentration and coronary artery calciﬁcation (CAC) in 50
patients with ischemic coronary disease has been investigated. We used ELISA method for measuring RANKL and OPG serum
concentrations. Results. There was a signiﬁcant correlation between RANKL:OPG serum concentration ratio and CAC in our
study population (P = 0.01). Conclusion. Our results suggested that RANKL:OPG ratio concentration has a potential of being
used as a marker for coronary artery disease.
1.Introduction
There is a considerable demand for diagnosis and treatment
of the pathologic conditions that underlie sudden cardiac
events such as acute coronary syndromes and sudden cardiac
death. Some people experience a cardiovascular event, while,
by Framingham scores, they were not considered to be
at high-risk group [1, 2]. Atherosclerotic calciﬁcation is a
failure that can make the break in the vessels and cause the
plaque rupture [3, 4]. Plaque rupture is the most common
type of plaque complications. Several retrospective autopsy
series and a few cross-sectional clinical studies have sug-
gested that thrombotic coronary death and acute coronary
syndromes are caused by the plaque features [5, 6]. This
phenomenon is a regular and organized process that is so
similar to osteoproduction [7]. Some of the smooth muscle
cells along the migration from layer to vascular media layer
go osteogenic [8]. These cells continuously express osteopro-
teins such as RANKL and OPG [4] and start to store the
collagenicextracellularmatrixinmineralizedcollectionsthat
ﬁnally cause vascular calciﬁcation [9]. RANKL/RANK/OPG
system has an important role in several aspects of the
processes leading to calciﬁcation [3]. RANKL binds to its
membranereceptorRANKandproducesseveralintracellular
signals that regulate the fusion, development, function,
and survival of the osteoclasts [2, 3]. It also stimulates2 Thrombosis
the gradual development of osteogenic calciﬁcation in the
vascular smooth muscle cells [10]. OPG as a soluble scav-
enger presents the RANKL/RANK binding so it inhibits the
RANKL function [3]. It has inhibitory eﬀects on osteoclasto-
genes and osteogenic resorption [2]. Some reports indicated
that, in cardiovascular system, serum concentration of OPG
increases in clinical cases susceptible to atherosclerosis and
unstable vascular calciﬁcation [3] OPG secretion probably
is an imperfect compensatory mechanism in response to
increase of RANKL secretion that could prevent calciﬁcation
and atherosclerosis [11]. So increased RANKL concentration
and decreased OPG level both can lead to vascular calci-
ﬁcation. According to this, we evaluated the RANKL/OPG
ratio as a diagnostic biomarker to determine the extent
of vascular calciﬁcation and subsequent coronary disorders
such as coronary artery calciﬁcation (CAC).
2. Patientsand Methods
2.1. Patients. Fifty patients with ischemic coronary disease
(37 men and 13 women, age 18–60) were enrolled in
this study between November 2008 and September 2009.
Patients were from Razavi Hospital in Mashhad. Patients
with calcium and phosphorous metabolic failure, parathy-
roid disease, renal dysfunction, history of osteodisorder,
zero calcium score, and vit D consumption were excluded
from the study. A questionnaire containing demographic
data, laboratory data, drug history, medical history, familial
history of CV risk factors was completed for all patients. All
patients signed the consent form prior to entry in the study.
2.2.BloodSamplingandBiochemicalAssay. Wholebloodwas
collected from patients and centrifuged at 2500rpm for
10min. The plasma fraction was isolated and stored at
−70◦C until required for analysis. Routine biochemical mea-
surements such as plasma glucose, total cholesterol (TC),
triglycerides, low density lipoprotein cholesterol (LDL),
high-density lipoprotein cholesterol (HDL), serum calcium,
phosphorus were carried out by routine laboratory methods.
2.3.DeterminationofOPGandRANKLSerumConcentration.
Serum level of soluble OPG and RANKL was measured
with an enzyme-linked immunosorbant assay (ELISA) kit
(Apotech, Switzerland); each assay was calibrated using
RANKL and OPG standard curve following the manufac-
turer’s instructions.
2.4. Statistical Analysis. Statistical analysis was carried out
by SPSS 11.5. Correlation between serum concentration of
RANKL, OPG, and RANKL/OPG ratio with CAC (coronary
artery calciﬁcation) was analyzed using Pearson correla-
tion. To compare serum concentration of RANKL, OPG,
and RANKL/OPG ratio between diﬀerent groups, one-way
ANOVA test was used. Results were considered signiﬁcant at
P<0.05. All measured values are presented as the mean ±
SD.
Table 1: Demographic data, laboratory tests, and traditional car-
diovascular risk factors of patients.
Age (year) 56.52 ±11.05
Female/male ratio 0.35
Mean BMI 28.21 ±4.69
Laboratory test
Calcium (ng/dL) 9.02 ±2.14
Phosphorous (ng/dL) 3.78 ±1.35
HDL cholesterol (mg/dL) 43.95 ±14.1
LDL cholesterol (mg/dL) 97.87 ±35.4
Total cholesterol (mg/dL) 171.72 ±40.63
FBS (mg/dL) 103.28 ± 30
Mean concentration of RANKL (pg/mL)
(CV) 687.14 ±114.23 (0.16)
Mean concentration of OPG (pg/mL)
(CV) 6.03 ±0.786 (0.13)
RANKL/OPG ratio (CV) 267.86 ±31.23 (0.12)
Total calciﬁcation of coronary vessels
(agatson) 356.27 ±44.13
Calciﬁcation in coronary LAD (agatson) 234.17 ±32.96
Calciﬁcation in coronary RCA (agatson) 63.885 ±10.92
Calciﬁcation in coronary CX (agatson) 49.09 ±10.59
Calciﬁcation in coronary LM (agatson) 8.49 ±2.55
Traditional cardiovascular risk factors
Hypertension (%) 54.84
Dyslipidemia (%) 73
Positive family history (%) 46
Diabetes (%) 17
Current smoking (%) 13
3. Results
3.1. Characteristics of the Study Population. Demographic
data, biochemical data (laboratory tests) including OPG and
RANKL levels, and traditional cardiovascular risk factors are
summarized in Table 1.
3.2. Correlation between RANKL:OPG Ratio and Total Coro-
nary Artery Calciﬁcation. There was a signiﬁcant positive
correlation between RANKL:OPG ratio and total coronary
artery calciﬁcation (Table 2 and Figure 1) and negative cor-
relation between OPG and total coronary artery calciﬁcation
(Table 2). There was no signiﬁcant correlation between
RANKL serum concentration coronary artery calciﬁcation
(Table 2).
4. Discussion
RANKL:OPG ratio showed stronger correlation with CAC
than either RANKL or OPG concentration.
Presence and extent of vascular calciﬁcation are mainly
relatedtoincidenceofcardiovasculardisorders[11].RANKL
is expressed and secreted in the semisteoblastic cells in
atherosclerotic lesions and causes the gradual developmentThrombosis 3
Table 2: Correlation between RANKL:OPG ratio, serum concentration of OPG, and RANKL with LAD, RCA, LMCA, and Cx coronary
artery calciﬁcation.
Serum RANKL concentration Serum OPG concentration RANKL/OPG
P value1 CC2 P value CC P value CC
Total CAC3 0.2 −0.214 0.03 −0.468 0.01 0.519
CAC of LAD 0.39 −1.44 0.013 −0.4 0.001 0.545
CAC of RCA 0.17 −0.227 0.033 −0.35 0.16 0.234
CAC of LMCA 0.71 −0.62 0.42 −0.135 0.73 0.058
CAC of CX 0.21 −0.208 0.07 −0.298 0.21 0.209
1Pearson correlation test, 2Correlation coeﬃcient, 3Coronary artery calciﬁcation.
of vascular osteogenic calciﬁcation [12]. OPG concentration
also increases in unstable vascular calciﬁcations and other
vascular disorders. Although OPG can prevent the eﬀects of
RANKL by anatomization, maybe this increment in OPG
serum level, as a protective, is not enough to neutralize
the RANKL eﬀects [13, 14]. There are several reports
that indicated the relationship between OPG and RANKL
eﬀects and vascular calciﬁcation [15]. Some studies have
shown that OPG can protect large blood vessels from
arterial calciﬁcation based on the observation of renal and
aortic calciﬁcations occurring in OPG knockout mice [16].
Intravascular administration of OPG could prevent the
induced calciﬁcation by high dose of vit D in rats [17]. It is
considered that the serum concentration of RANKL was in
the highest level in acute vascular syndromes such as acute
myocardial infarction and ischemic cerebral vascular attacks
[18] .A l lo fp r e v i o u ss t u d i e sj u s te v a l u a t e dt h eR A N K Lo r
OPG, almost OPG, eﬀects on development of CAC. As
these factors, RANKL, RANK, and OPG, are members of
one system and strongly associated, the previous results
are conﬂicting. Some studies reported the increased serum
level of OPG in CAC, while there are other evidence of
inhibitory eﬀects of OPG on vascular calciﬁcation [19].
Therefor, it is considered that evaluation of any of these
factorsalone cannotbe usefulasadiagnostic biomarker. Our
study for the ﬁrst time determined the changes in RANKL
and OPG levels concomitantly and reported the results as
RANKL/OPG ratio. As we reported, there is no signiﬁcant
relation between RANKL serum levels and CAC (P =
0.2) but there is signiﬁcant negative relation between OPG
serum (P = 0.03, CC = −0.468) and CAC and signiﬁcant
positive relation between RANKL/OPG ratio and CAC. It is
important to mention that, in this study, measurement of
OPG and RANKL level was performed in stable coronary
disorders such as stable angina. In these patients, the less
serum OPG levels are, the more calciﬁcation intensity
occurred; this indicates the protective eﬀects of OPG in
vascular calciﬁcation. Other reports about these two factors
belonged to researches on coronary syndromes such as acute
myocardial infarction; therefore, it seems that the results of
these two types of studies are not comparable. According
to these facts, it is concluded that, in cardiovascular events,
OPG serum level as a preventive compensatory mechanism
markedly increased but this is not enough to neutralize the
RANKL level increment. However, as a main limitation of
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Figure 1: Correlation between RANKL:OPG ratio and coronary
artery calciﬁcation.
the cross-sectional design, the RANKl/OPG ratio assessed
together with the CAC is not necessarily this occurring
at the same time. In conclusion, our study showed that
determination of the RANKl/OPG ratio in compare with
eachofthesetwofactorsaloneisabetterdiagnosticindicator
for intensity of vascular calciﬁcation that leads to coronary
disorders such as CAC.
Disclosure
The authors have had no involvements that might raise the
question of bias in the work reported or in the conclusions,
implications, or opinion stated.
References
[1] M. Abedin, T. Omland, T. Ueland et al., “Relation of
osteoprotegerin to coronary calcium and aortic plaque (from
the Dallas Heart Study),” American Journal of Cardiology, vol.
99, no. 4, pp. 513–518, 2007.
[2] M. Abedin, Y. Tintut, and L. L. Demer, “Vascular calciﬁca-
tion: mechanisms and clinical ramiﬁcations,” Arteriosclerosis,
Thrombosis, and Vascular Biology, vol. 24, no. 7, pp. 1161–
1170, 2004.
[3] D. V. Anand, A. Lahiri, E. Lim, D. Hopkins, and R. Corder,
“The relationship between plasma osteoprotegerin levels and
coronary artery calciﬁcation in uncomplicated type 2 diabetic
subjects,”JournaloftheAmericanCollegeofCardiology,vol.47,
no. 9, pp. 1850–1857, 2006.4 Thrombosis
[4] Y. Asanuma, C. P. Chung, A. Oeser et al., “Serum osteo-
protegerin is increased and independently associated with
coronary-artery atherosclerosis in patients with rheumatoid
arthritis,” Atherosclerosis, vol. 195, no. 2, pp. e135–e141, 2007.
[ 5 ]B .F .B o y c ea n dL .X i n g ,“ B i o l o g yo fR A N K ,R A N K L ,
and osteoprotegerin,” Arthritis Research and Therapy, vol. 9,
supplement 1, article S1, 2007.
[ 6 ]M .J .B u d o ﬀ, S. Achenbach, R. S. Blumenthal et al., “Assess-
ment of coronary artery disease by cardiac computed tomog-
raphy: a scientiﬁc statement from the American Heart Asso-
ciation Committee on Cardiovascular Imaging and Interven-
tion, Council on Cardiovascular Radiology and Intervention,
and Committee on Cardiac Imaging, Council on Clinical
Cardiology,”Circulation,vol.114,no.16,pp.1761–1791,2006.
[7] P. Collin-Osdoby, “Regulation of vascular calciﬁcation by
osteoclast regulatory factors RANKL and osteoprotegerin,”
Circulation Research, vol. 95, no. 11, pp. 1046–1057, 2004.
[8] A. Crisafulli, A. Micari, D. Altavilla et al., “Serum levels of
osteoprotegerin and RANKL in patients with ST elevation
acute myocardial infarction,” Clinical Science, vol. 109, no. 4,
pp. 389–395, 2005.
[ 9 ]T .M .D o h e r t y ,L .A .F i t z p a t r i c k ,A .S h a h e e n ,T .B .R a j a v -
ashisth, and R. C. Detrano, “Genetic determinants of arterial
calciﬁcation associated with atherosclerosis,” Mayo Clinic
Proceedings, vol. 79, no. 2, pp. 197–210, 2004.
[10] Y. Liu and C. M. Shanahan, “Signalling pathways and vascular
calciﬁcation,” Frontiers in Bioscience, vol. 16, no. 4, pp. 1302–
1314, 2011.
[11] T.C.Gerber,“Diagnosticandprognosticimplicationsofcoro-
nary artery calciﬁcation detected by computed tomography,”
Calciﬁed Tissue International, vol. 91, pp. 123–137, 2009.
[12] J. Golledge, M. McCann, S. Mangan, A. Lam, and M. Karan,
“Osteoprotegerin and osteopontin are expressed at high
concentrations within symptomatic carotid atherosclerosis,”
Stroke, vol. 35, no. 7, pp. 1636–1641, 2004.
[13] P. C. Keelan, L. F. Bielak, K. Ashai et al., “Long-term prog-
nostic value of coronary calciﬁcation detected by electron-
beam computed tomography in patients undergoing coronary
angiography,” Circulation, vol. 104, no. 4, pp. 412–417, 2001.
[14] J. Shamsara, M. Ramezani, and A. H. Mohammadpour, “The
RANKL: osteoprotegerin (OPG) ratio as a new biomarker for
coronaryarterydisease,” IranianJournalofMedicalHypotheses
and Ideas, vol. 3, no. 1, 2009.
[15] M. Ketteler and C. Giachelli, “Novel insights into vascular
calciﬁcation.,” Kidney International. Supplement, no. 105, pp.
S5–S9, 2006.
[16] S. Kiechl, G. Schett, J. Schwaiger et al., “Soluble receptor acti-
vator of nuclear factor-κB ligand and risk for cardiovascular
disease,” Circulation, vol. 116, no. 4, pp. 385–391, 2007.
[17] M. C. L. Lim, T. W. Wong, L. O. Yaneza, C. De Larrazabal, J.
K. Lau, and H. K. Boey, “Non-invasive detection of signiﬁcant
coronary artery disease with multi-section computed tomog-
raphy angiography in patients with suspected coronary artery
disease,” Clinical Radiology, vol. 61, no. 2, pp. 174–180, 2006.
[18] C. E. Rackley and N. J. Weissman, “The role of plaque rupture
in acute coronary syndromes,” Arteriosclerosis, Thrombosis,
and Vascular Biology, vol. 54, pp. 743–759, 2009.
[19] C. E. Rackley, “Pathogenesis of atherosclerosis,” Atherosclero-
sis, vol. 202, pp. 167–174, 2009.